West Pharma shareholders approve amended 2016 Omnibus Plan; share reserve increased by 2M

WEST PHARMACEUTICAL SERVICES INC

Shareholders approved amendment effective May 6, 2025; total share reserve increased to 7,500,000 from 5,500,000.
Full value awards granted on/after May 6, 2025 count as 2.0 shares vs. 2.5 previously, reducing per-award dilution.
Most awards subject to minimum 12-month vesting; up to 5% of shares exempt from this requirement.
Non-employee director annual compensation cap raised to $800,000 (including cash).
Plan term extended to May 6, 2035; awards outstanding upon termination remain in effect.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.